Full Press Release Details
Computershare will be appointed US Transfer
Agent and Registrar to facilitate
Transfer Capabilities for Nasdaq-listed shares
Melbourne, Australia, 17 November 2023 -
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ( Incannex Australia') is pleased to announce that Incannex Healthcare
Inc. ( Incannex US'), which will become Incannex Australia's new parent company upon implementation of schemes of arrangement,
intends to appoint Computershare Trust Company, N.A. ( Computershare') as its US transfer agent and registrar upon implementation
of the schemes of arrangement. Computershare will be appointed to use its intuitive management platform to facilitate a seamless transition
from ASX to Nasdaq for security holders of Incannex Australia upon implementation of schemes of arrangement that have been approved by
security holders and an Australian federal court.
Security holders of Incannex Australia are required
to open an online account with Computershare, input their holding and identification details, permitting them direct access to their holding/s.
Key Features of Computershare Platform
Computershare has also been engaged to provide
extensive technical and management support to shareholders of Incannex Australia throughout the transition of their holdings from ASX
to Nasdaq. A dedicated telephone support hotline has been established to troubleshoot any account opening or management issues that security
holders may experience. Appendix 1 on the final page of this announcement provides relevant contact details.
Indicative Timeline upon Implementation of
28 November: Incannex US's shares
of common stock are expected to list on Nasdaq with trading commencing within 2-3 days as shares are balanced on the Nasdaq open market.
04 December: Holding statements for shareholders
Incannex Healthcare Limited (ABN: 93 096 635 246)
Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000
05 December: Holding statements are dispatched:
07 December: Anticipated arrival of statements
in Australia, then to be dispatched to all Australian shareholders via an express service to shareholders. Upon receipt of the statements,
shareholders will be required to follow the "Accessing Investor Center Shareholder Account" guide provided by mail and/or email.
This announcement has been approved for release
to ASX by the Incannex Australia's Board of Directors.
About Incannex Healthcare Limited
Incannex is a clinical stage pharmaceutical development
company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive
sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis,
inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
U.S. FDA approval and registration, subject to
ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently
has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic
opportunities to Incannex and its shareholders.
Incannex has a strong patent filing strategy in
place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. Incannex holds
20 granted patents and over 30 pending patent applications.
Website: www.incannex.com.au
Investors: investors@incannex.com.au
Incannex Healthcare Limited (ABN: 93 096 635 246)
Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000
Forward-looking statements
This press release contains "forward-looking
statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates,
as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's
views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change.
Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information,
future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date
after the date of this press release.
Contact Information:
Incannex Healthcare Limited and Incannex Healthcare
Chief Executive Officer
Investor Relations Contact - United States
Incannex Healthcare Limited (ABN: 93 096 635 246)
Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000
Appendix 1: Resolutions to Technical Difficulties
For shareholders that encounter difficulties in accessing their online
account, please ring the following dedicated support line:
+1 888-729-5707 - Toll Free Number
+1 781-575-2072 - Local/DID Number
Other Steps to Resolve Access Issues:
PIN Code Delay (if waiting for a PIN code by mail):
Shareholders can email IssuerSupport@computershare.com to request a
PIN code to be sent directly to the shareholder's email. Note that this process takes 3-4 business days and requires prior online registration.
Example Email: To: issuersupport@computershare.com
Subject: Incannex (IXHL)- Email PIN Code Authorization -
C***#### Body: Hello, please email the PIN code to shareholdersemail@XXXXX.com for the account C***####.
Assistance with Online Access:
In cases where a shareholder has attempted to contact the dedicated
line without success, the shareholder can request direct assistance from Computershare:
Example Email: To: issuersupport@computershare.com Subject: Incannex
(IXHL) - Shareholder Assistance Needed - C***#### Body: Hello, please reach out to Mr. Shareholder to assist in setting up
their online investor center account. shareholdersemail@gmail.com, Shareholder Phone #, and Shareholder's timezone for the account
Please note: The second option should be utilized as a last
resort if a shareholder has already tried the dedicated line and is still unable to access their account.
Incannex Healthcare Limited (ABN: 93
Level 39, Rialto South Tower, 525 Collins
Street, Melbourne VIC 3000